Citations

Clear

959 citation(s) found for "Service, F J".

Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease
Reynolds, Harmony R. , Picard, Michael H. , Spertus, John A. , Peteiro, Jesús , López‐Sendón, José , Senior, Roxy , El‐Hajjar, Mohammad , Čelutkienė, Jelena , Shapiro, Michael D. , Pellikka, Patricia A. , Kunichoff, Dennis , Anthopolos, Rebecca , Abdul-Nour, Khaled, Khouri, Michel G. , Берштейн, Л. Л. , Beltrame, John F. , Min, James K. , Fleg, Jerome L. , Li, Yi , Hochman, Judith S. , Lopez Sendon, Jose Luis , Bershtein, Leonid , Beltrame, John F , Hochman, Judith S , Pellikka, Patricia A , Peteiro, Jesus , Spertus, John A , Shapiro, Michael D , Celutkiene, Jelena , Reynolds, Harmony R , Alfakih, Khaled , Belder, Mark de , Poh, Kian Keong , Maron, David J.

Mayo Clinic

Circulation | June 1, 2021 | Volume: 144 | Issue: 13 | Pages: 1008-1023

10.1161/circulationaha.120.046791 | PMID 34058845 Get It

Background: Ischemia with no obstructive coronary artery disease (INOCA) is common and has an adverse prognosis. We set out to describe the natural history of symptoms and ischemia in INOCA. Methods: CIAO-ISCHEMIA (Changes in Ischemia and Angina over One Year in ISCHEMIA Trial Screen Failures With INOCA) was an international cohort study conducted from 2014 to 2019 involving angina assessments (Seattle Angina Questionnaire) and stress echocardiograms 1 year apart. This was an ancillary study that included patients with a history of angina who were not randomly assigned in the ISCHEMIA trial. Stress-induced wall motion abnormalities were determined by an echocardiographic core laboratory blinded to symptoms, coronary artery disease status, and test timing. Medical therapy was at the discretion of treating physicians. The primary outcome was the correlation between the changes in the Seattle Angina Questionnaire angina frequency score and changes in echocardiographic ischemia. We also analyzed predictors of 1-year changes in both angina and ischemia, and we compared CIAO participants with ISCHEMIA participants with obstructive coronary artery disease who had stress echocardiography before enrollment, as CIAO participants did. Results: INOCA participants in CIAO were more often female (66% of 208 versus 26% of 865 ISCHEMIA participants with obstructive coronary artery disease, P <0.001), but the magnitude of ischemia was similar (median 4 ischemic segments [interquartile range, 3–5] both groups). Ischemia and angina were not significantly correlated at enrollment in CIAO ( P =0.46) or ISCHEMIA stress echocardiography participants ( P =0.35). At 1 year, the stress echocardiogram was normal in half of CIAO participants, and 23% had moderate or severe ischemia (≥3 ischemic segments). Angina improved in 43% and worsened in 14%. Change in ischemia over 1 year was not significantly correlated with change in angina (ρ=0.029). Conclusions: Improvement in ischemia and angina were common in INOCA but not correlated. Our INOCA cohort had a degree of inducible wall motion abnormalities similar to concurrently enrolled ISCHEMIA participants with obstructive coronary artery disease. Our results highlight the complex nature of INOCA pathophysiology and the multifactorial nature of angina. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02347215.
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study
Zivanovic, Oliver , Zhou, Qin , Iasonos, Alexia , Makker, Vicky , Brown, Amy, Nerenstone, Stacy, Schroeder, E.D., Soldan, Krysten, Su, Katy , Gardner, Ginger J. , Andikyan, Vaagn , Guo, Jianxia , Jewell, Elizabeth L. , Roche, Kara Long , Troso-Sandoval, Tiffany A. , Lichtman, Stuart M. , Moukarzel, Lea A. , Dessources, Kimberly , Abu‐Rustum, Nadeem R. , Aghajanian, Carol , Tew, William P. , Sonoda, Yukio, Iasonos, Alexia , Konner, Jason A , Makker, Vicky , Langstraat, Carrie L , Paroder, Viktoriya , Lakhman, Yulia , Su, Katy , Gardner, Ginger J , Jewell, Elizabeth L , Troso-Sandoval, Tiffany , Lichtman, Stuart M , Tew, William P , Beumer, Jan Hendrik , Sonoda, Yukio , O'Cearbhaill, Roisin E , Moukarzel, Lea A , Dennis, S. , Grisham, Rachel Nicole , Diaz, John Paul , Langstraat, Carrie , Lakhman, Yulia

Mayo Clinic

Journal of Clinical Oncology | May 21, 2021 | Volume: 39 | Issue: 23 | Pages: 2594-2604

10.1200/jco.21.00605 | PMID 34019431 Get It

PURPOSEThe purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery.MATERIALS AND METHODSPatients were intraoperatively randomly assigned to carboplatin HIPEC (800 mg/m2for 90 minutes) or no HIPEC, followed by five or six cycles of postoperative IV carboplatin-based chemotherapy, respectively. Based on a binomial single-stage pick-the-winner design, an arm was considered winner if ≥ 17 of 49 patients were without disease progression at 24 months post-surgery. Secondary objectives included postoperative toxicity and HIPEC pharmacokinetics.RESULTSOf 98 patients, 49 (50%) received HIPEC. Complete gross resection was achieved in 82% of the HIPEC patients and 94% of the standard-arm patients. Bowel resection was performed in 37% of patients in the HIPEC arm compared with 65% in the standard ( P = .008). There was no perioperative mortality and no difference in use of ostomies, length of stay, or postoperative toxicity. At 24 months, eight patients (16.3%; 1-sided 90% CI, 9.7 to 100) were without progression or death in the HIPEC arm and 12 (24.5%; 1-sided 90% CI, 16.5 to 100) in the standard arm. With a medium follow-up of 39.5 months, 82 patients progressed and 37 died. The median progression-free survival in the HIPEC and standard arms were 12.3 and 15.7 months, respectively (hazard ratio, 1.54; 95% CI, 1 to 2.37; P = .05). There was no significant difference in median overall survival (52.5 v 59.7 months, respectively; hazard ratio, 1.39; 95% CI, 0.73 to 2.67; P = .31). These analyses were exploratory.CONCLUSIONHIPEC with carboplatin was well tolerated but did not result in superior clinical outcomes. This study does not support the use of HIPEC with carboplatin during secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer.
Does the Age of Sudden Cardiac Death in Family Members Matter in Brugada Syndrome?
Kewcharoen, Jakrin , Kanitsoraphan, Chanavuth , Barry, Timothy , Shanbhag, Anusha , Ko, Nway L. Ko, Vutthikraivit, Wasawat , Home, Madhurima , Agasthi, Pradyumna , Ashraf, Hasan , Shen, Win‐Kuang , Ko Ko, Nway L, Kewcharoen, Jakrin , Kanitsoraphan, Chanavuth , Rattanawong, Pattara , Ashraf, Hasan , Shimizu, Wataru

Mayo Clinic

Journal of the American Heart Association | May 20, 2021 | Volume: 10 | Issue: 11 | Pages: No page available

10.1161/jaha.120.019788 | PMID 34013737 Get It

Background Brugada syndrome is an inherited cardiac channelopathy associated with major arrhythmic events (MAEs). The presence of a positive family history of sudden cardiac death (SCD) as a risk predictor of MAE remains controversial. We aimed to examine the association between family history of SCD and MAEs stratified by age of SCD with a systematic review and meta‐analysis. Methods and Results We searched the databases of MEDLINE and EMBASE from January 1992 to January 2020. Data from each study were combined using the random‐effects model. Fitted metaregression was performed to evaluate the association between the age of SCD in families and the risk of MAE. Twenty‐two studies from 2004 to 2019 were included in this meta‐analysis involving 3386 patients with Brugada syndrome. The overall family history of SCD was not associated with increased risk of MAE in Brugada syndrome (pooled odds ratio [OR], 1.11; 95% CI, 0.82–1.51; P =0.489, I 2 =45.0%). However, a history of SCD in family members of age younger than 40 years of age did increase the risk of MAE by ≈2‐fold (pooled OR, 2.03; 95% CI, 1.11–3.73; P =0.022, I 2 =0.0%). When stratified by the age of cut point at 50, 45, 40, and 35 years old, a history of SCD in younger family member was significantly associated with a higher risk of MAE (pooled OR, 0.49, 1.30, 1.51, and 2.97, respectively; P =0.046). Conclusions A history of SCD among family members of age younger than 40 years was associated with a higher risk of MAE.
Transfusion service disaster planning
Bundy, Kelly, Foss, Mary , Stubbs, James R.

Mayo Clinic

Immunohematology | May 20, 2021 | Volume: 24 | Issue: 3 | Pages: 93-101

10.21307/immunohematology-2019-279 Get It

Abstract The Mayo Clinic, in Rochester, Minnesota, recently set forth a directive to develop a Mayo Emergency Incident Command System (MEICS) plan to respond to major disasters. The MEICS plan that was developed interfaces with national response plans to ensure effective communication and coordination between our institution and local, state, and federal agencies to establish a common language and communication structure. The MEICS plan addresses multiple aspects of dealing with resource needs during a crisis, including the need for blood and transfusion medicine services. The MEICS plan was developed to supplement our current local emergency preparedness procedures and provide a mechanism for responding to the escalating severity of an emergency to deal with situations of a magnitude that is outside the normal experience. A plan was developed to interface the existing Transfusion Medicine disaster plan standard operating procedures (SOP) with the institutional and Department of Laboratory Medicine (DLMP) MEICS plans. The first step in developing this interface was defining MEICS. Other major steps were defining the chain of command, developing a method for visually indicating who is “in charge,” planning communication, defining the actions to be taken, assessing resource needs, developing flowcharts and updating SOPs, and developing a blood rationing team to deal with anticipated blood shortages. Several key features of the interface and updated disaster plan that were developed are calling trees for response personnel, plans for relocating leadership to alternative command centers, and action sheets to assist with resource assessment. The action sheets also provide documentation of key actions by response personnel. Immunohematology 2008;24:93–101 .
Ramadan fasting: recommendations for patients with cardiovascular disease
Akhtar, Abid Mohammed , Ghouri, Nazim , Chahal, C. Anwar A. , Patel, Riyaz , Sattar, Naveed , Waqar, Salman , Khanji, Mohammed Y , Sattar, Naveed , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Ricci, Fabrizio

Mayo Clinic

Heart | May 14, 2021 | Volume: 108 | Issue: 4 | Pages: 258-265

10.1136/heartjnl-2021-319273 | PMID 33990414 Get It

Ramadan fasting is observed by most of the 1.8 billion Muslims around the world. It lasts for 1 month per the lunar calendar year and is the abstention from any food and drink from dawn to sunset. While recommendations on ‘safe’ fasting exist for patients with some chronic conditions, such as diabetes mellitus, guidance for patients with cardiovascular disease is lacking. We reviewed the literature to help healthcare professionals educate, discuss and manage patients with cardiovascular conditions, who are considering fasting. Studies on the safety of Ramadan fasting in patients with cardiac disease are sparse, observational, of small sample size and have short follow-up. Using expert consensus and a recognised framework, we risk stratified patients into ‘low or moderate risk’, for example, stable angina or non-severe heart failure; ‘high risk’, for example, poorly controlled arrhythmias or recent myocardial infarction; and ‘very high risk’, for example, advanced heart failure. The ‘low-moderate risk’ group may fast, provided their medications and clinical conditions allow. The ‘high’ or ‘very high risk’ groups should not fast and may consider safe alternatives such as non-consecutive fasts or fasting shorter days, for example, during winter. All patients who are fasting should be educated before Ramadan on their risk and management (including the risk of dehydration, fluid overload and terminating the fast if they become unwell) and reviewed after Ramadan to reassess their risk status and condition. Further studies to clarify the benefits and risks of fasting on the cardiovascular system in patients with different cardiovascular conditions should help refine these recommendations.
Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study
Fribance, Sarah , Pikis, Stylianos , Lee, John Y. K. , Buch, Love, Bernstein, Kenneth , Mathieu, David , Perron, Rémi, Patel, Samir , Álvarez, Roberto Martínez , Moreno, Nuria Martínez , Lee, Cheng‐Chia , Strickland, Ben A. , Zada, Gabriel , Chang, Eric L. , Kondziolka, Douglas , Sheehan, Jason P. , Mathieu, David , Kondziolka, Douglas , Bunevičius, Adomas , Moran, Michael, Yang, Andrew I. , Liščák, Roman , Šimonová, Gabriela , Trifiletti, Daniel M. , Yang, Huai‐Che

Mayo Clinic

Thyroid® | May 12, 2021 | Volume: 31 | Issue: 8 | Pages: 1244-1252

10.1089/thy.2020.0947 | PMID 33978475 Get It

Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1–10 BMs). The median SRS treatment volume was 0.79 cm 3 (range: 0.003–38.18 cm 3 ), and the median SRS prescription dose was 20 Gy (range: 8–24 Gy). The median survival after SRS for BMs was 14 months (range: 3–58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143–11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689–0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.
Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review
Bataillard, Edward , Cheah, Chan Y. , Maurer, Matthew J. , Khurana, Arushi , Eyre, Toby A. , El‐Galaly, Tarec Christoffer , Bataillard, Edward J , Cheah, Chan Yoon , Maurer, Matthew , El-Galaly, Tarec C

Mayo Clinic

Blood Advances | May 8, 2021 | Volume: 5 | Issue: 9 | Pages: 2426-2437

10.1182/bloodadvances.2021004665 | PMID 33961018 Get It

Abstract The dilemma of whether to treat elderly patients with diffuse large B-cell lymphoma (DLBCL) with a full or reduced dose intensity (DI) of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone+rituximab) is often faced by clinicians. We conducted a systematic review assessing the impact of R-CHOP DI on DLBCL survival outcomes, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) guidelines. We searched MEDLINE, EMBASE, and Cochrane CENTRAL for studies with ≥100 patients treated with R-CHOP/R-CHOP–like therapies published from January 2002 through November 2020. Studies were included if they reported the impact of R-CHOP DI on survival outcomes. We screened records, extracted data, and reviewed all the studies for quality and statistical appraisal. Of 380 screened records, 13 studies including 5188 patients were reviewed. DI was often calculated as the ratio of the cumulative delivered dose of prespecified drug(s) to the cumulative planned dose multiplied by a time-correction factor. Lower DI (intended or relative) was associated with inferior survival in 7 of 9 studies reporting crude survival analyses. Multivariable analysis using DI as a covariate was performed in 10 studies. Six showed an association (P &lt; .05) with adjustment for other covariates, and 4 did not. Most studies and those larger studies of higher quality showed poorer outcomes associated with reduced DI. In subgroups aged ≥80 years, survival was not consistently affected by reduced DI. DI-specific randomized trials are warranted, but these data support full-dose R-CHOP in elderly and fit patients aged &lt;80 years with DLBCL, but not in those aged ≥80 years, where dose-reduced R-CHOP does not appear to compromise survival.
Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma
Vogt, Samantha L. , Patel, Moosa , Lakha, Atul , Philip, Vinitha , Omar, Tanvier , Ashmore, Philippa , Pather, Sugeshnee , Haley, Lisa , Zheng, Gang , Mayne, Elizabeth , Stevens, Wendy , Wagner‐Johnston, Nina D. , Gocke, Christopher D. , Martinson, Neil , Ambinder, Richard F. , Xian, Rena R. , Gocke, Christopher D , Ambinder, Richard F , Stone, Jennifer

Mayo Clinic

JCO Global Oncology | April 28, 2021 | Volume: No volume available | Issue: 7 | Pages: 611-621

10.1200/go.20.00651 | PMID 33909482 Get It

PURPOSEDiagnosis of AIDS lymphoma in low-resource settings, like South Africa, is often delayed, leaving patients with limited treatment options. In tuberculosis (TB) endemic regions, overlapping signs and symptoms often lead to diagnostic delays. Assessment of plasma cell-free DNA (cfDNA) by next-generation sequencing (NGS) may expedite the diagnosis of lymphoma but requires high-quality cfDNA.METHODSPeople living with HIV with newly diagnosed aggressive B-cell lymphoma and those with newly diagnosed TB seeking care at Chris Hani Baragwanath Academic Hospital and its surrounding clinics, in Soweto, South Africa, were enrolled in this study. Each participant provided a whole blood specimen collected in cell-stabilizing tubes. Quantity and quality of plasma cfDNA were assessed. NGS of the immunoglobulin heavy chain was performed.RESULTSNine HIV+ patients with untreated lymphoma and eight HIV+ patients with TB, but without lymphoma, were enrolled. All cfDNA quantity and quality metrics were similar between the two groups, except that cfDNA accounted for a larger fraction of recovered plasma DNA in patients with lymphoma. The concentration of cfDNA in plasma also trended higher in patients with lymphoma. NGS of immunoglobulin heavy chain showed robust amplification of DNA, with large amplicons (> 250 bp) being more readily detected in patients with lymphoma. Clonal sequences were detected in five of nine patients with lymphoma, and none of the patients with TB.CONCLUSIONThis proof-of-principle study demonstrates that whole blood collected for cfDNA in a low-resource setting is suitable for sophisticated sequencing analyses, including clonal immunoglobulin NGS. The detection of clonal sequences in more than half of patients with lymphoma shows promise as a diagnostic marker that may be explored in future studies.
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, Dipesh H. , Paine, Peter , Black, Christopher J. , Houghton, Lesley A. , Everitt, Hazel , Corsetti, Maura , Aziz, Imran , Farmer, Adam D. , Eugenicos, Maria , Moss‐Morris, Rona , Yiannakou, Yan , Ford, Alexander C. , Aziz, Imran , Ford, Alexander C , Houghton, L A , Corsetti, M , Black, Christopher J , Vasant, Dipesh H , Farmer, Adam D , Agrawal, Anurag

Mayo Clinic

Gut | April 26, 2021 | Volume: 70 | Issue: 7 | Pages: 1214-1240

10.1136/gutjnl-2021-324598 | PMID 33903147 Get It

Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.